Medication nonadherence costs the U.S. healthcare system about $290 billion per year, according to New England Healthcare Institute. That big and scary number — the kind whose sheer enormity can make one’s eyes glaze over — is now even bigger.
Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.
Legislation proposed in the House of Representatives would speed up Food and Drug Administration approval of knock-off versions of vaccines and other biologics while requiring the agency to conduct more inspections of drug factories overseas, according to published reports.
Walgreens on Tuesday infused greater value into its Prescription Savings Club program, which now offers discounts on more than 8,000 brand-name and generic prescriptions, thanks to the inclusion of more than 700 "value-priced" generics, which retail as low as $12 for a 90-day supply.
Kerr Drug announced the launch of its Healthy Pet program, offering a full range of pet medications that customers can order on the chain's website and have delivered to their homes, the regional retail pharmacy chain said Wednesday.
The Food and Drug Administration should apply consistent regulatory standards across all biologics, Sandoz plans to state Friday in testimony at an FDA public hearing on draft guidances related to the development of biosimilars.
An organization that promotes efforts to stop prescription drug abuse announced Tuesday the release of a mobile app that directs users to places where they can safely get rid of unwanted and unused medications.
Consumption of probiotics is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA, the Journal of the American Medical Association.
The number of new drug shortages has been halved as early notifications from manufacturers of potential shortages have increased sixfold, the commissioner of the Food and Drug Administration wrote Thursday.
The recent loss of business from a key specialty pharmacy customer and the continued deluge of generic introductions will represent significant challenges for Cardinal Health in fiscal year 2013 as it approaches the year-end of its fiscal 2012, company executives told analysts during a conference call Thursday morning.